Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Current Deferred Revenue (2016 - 2019)

CorMedix's Current Deferred Revenue history spans 5 years, with the latest figure at $2206.0 for Q4 2019.

  • For Q4 2019, Current Deferred Revenue fell 80.0% year-over-year to $2206.0; the TTM value through Dec 2019 reached $2206.0, down 80.0%, while the annual FY2019 figure was $2206.0, 80.0% down from the prior year.
  • Current Deferred Revenue for Q4 2019 was $2206.0 at CorMedix, down from $4411.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $131066.0 in Q3 2016 and bottomed at $2206.0 in Q4 2019.
  • The 5-year median for Current Deferred Revenue is $20974.5 (2016), against an average of $52923.8.
  • The largest annual shift saw Current Deferred Revenue skyrocketed 318.44% in 2017 before it crashed 87.52% in 2018.
  • A 5-year view of Current Deferred Revenue shows it stood at $130409.0 in 2015, then dropped by 20.09% to $104210.0 in 2016, then dropped by 15.17% to $88404.0 in 2017, then plummeted by 87.52% to $11029.0 in 2018, then crashed by 80.0% to $2206.0 in 2019.
  • Per Business Quant, the three most recent readings for CRMD's Current Deferred Revenue are $2206.0 (Q4 2019), $4411.0 (Q3 2019), and $6600.0 (Q2 2019).